Milestone Scientific Inc. (MLSS)

Milestone Scientific's stock has experienced a significant decline, falling by 71.65% from April 9, 2025, to April 8, 2026. Key events impacting the stock include the Q4 2025 earnings report, which reported a net loss and missed revenue estimates, an amended agreement to enhance financing flexibility, and the announcement of a 2026 revenue plan and breakeven target. The company also launched Advisor Programs and reported Q3 2025 earnings. New strategic initiatives were implemented under the new CEO, focusing on direct sales, digital marketing, and a relaunch of CompuFlo.

There is no explicit information detailing the seasonal demand patterns for Milestone Scientific's specific products or services. General market trends in the dental and medical device industries can indirectly influence demand. Factors affecting market acceptance and demand include perceived safety and effectiveness, cost-effectiveness, convenience, reliability, patient satisfaction, product availability, warranty and technical support, and reimbursement availability.

Milestone Scientific, Inc. is a biomedical technology company specializing in computer-controlled injection technologies for local anesthesia and pain management, operating within the Healthcare sector. Its proprietary systems enhance patient comfort, improve clinical outcomes, and streamline anesthetic administration in dental and medical procedures. Key products include The Wand® / CompuDent® and STA Single Tooth Anesthesia System®, CompuFlo® Epidural System, CompuMed®, and DPS Dynamic Pressure Sensing Technology®.

Milestone Scientific distributes its technologies across North America, Europe, Latin America, and parts of Asia through direct sales and partnerships. Its dental devices are sold in the United States, U.S. territories, Canada, and 60 other countries. Export sales constituted approximately 45% of the company's revenue in 2025. The company is also actively pursuing regulatory approvals to expand its market presence in Japan, India, and Mexico.

Milestone Scientific's brand reputation presents a mixed picture. The company has a "Buy" consensus rating from analysts, with a significant upside from its current price and projected sales growth. Improved profitability and the appointment of new leadership are seen as positive factors. However, ongoing operating losses, missed earnings forecasts, potential financial challenges, and insider selling activity have negatively impacted its reputation.

Milestone Scientific's stock ownership is a mix of institutional, retail, and individual investors. Institutional investors hold between 5.79% and 6.44% of the stock, while insiders hold between 10.64% and 12.51%. Major institutional owners include Vanguard Group Inc., Geode Capital Management LLC, and Citadel Advisors Llc. Significant individual insider owners include Mr. Leonard Osser and Mr. Neal Goldman.